EAACI Congress 2024
BackOAS 19 - Breakthroughs in management of Hereditary Angioedema
Sunday 02 Jun, 08:30 AM -
10:00 AM Valencia, Spain
Bilbao
Oral Abstract Sessions
08:30
CRISPR-based gene editing of KLKB1 resulted in long-term plasma kallikrein protein reduction and decreased attack rate in patients with hereditary angioedema: Updated results from a phase 1 study
08:42
Burden Of Hereditary Angioedema and Impact on Quality Of Life: Final Data From a Multinational Patient Survey
08:54
Angioedema due to acquired C1-inhibitor deficiency associated to monoclonal gammopathies of undetermined significance - Characteristics of a French national cohort
09:06
Effectiveness and safety of berotralstat in patients with hereditary angioedema with normal C1-inhibitor: A European case series
09:18
Angioedema due to acquired C1-inhibitor deficiency and lymphoid hemopathies
09:30
Real-World Effectiveness and Safety of Lanadelumab for Hereditary Angioedema Attack Prophylaxis: A 3-Year Interim Analysis of the ENABLE Study
09:42
Clinical profile and management of pediatric hereditary angioedema in resource constrained settings: our experience from a single centre in North India